Compare Macy's Inc (M) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs ResMed Inc. — how do they compare? Macy's Inc trades at $22.67 (market cap $5.95B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 5.4× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and ResMed Inc. for 51 Days on average.
| M | RMD | |
|---|---|---|
Market Cap | $5.95B | $31.89B |
Volume | 6,030,644 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $275.96 |
52-Week Low | $16.51 | $182.82 |
Typical Hold Time | 58 Days | 51 Days |
Enterprise Value | $9.75B | $31.24B |
Dividend Yield | 3.36% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $22.79 with strong valuation metrics including a P/E of 8.35 and P/S of 0.27, indicating potential undervaluation. The stock shows bullish technical signals with recent earnings beats in Q2 2026 and raised 2026 guidance. Cash flow improved to $273M in 2025, while revenue stabilized at $23.01B with net income of $582M. The company's 'Bold New Chapter' strategy is driving digital transformation and omnichannel growth.
Investment outlook appears favorable with 31.7% analyst buy ratings and $24.25 consensus price target suggesting 6.4% upside. Key risks include retail sector competition and uneven quarterly performance, but strong dividend yield and turnaround progress support total return potential for patient investors.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
